Contribution: Industrial Research Assistance Program – Contributions to Firms
NEURENATI THERAPEUTIQUE INC./NEURENATI THERAPEUTICS INC.
$250,000.00
Preclinical development of a combination therapy for the treatment of Hirschsprung disease in newborns
FY 2025-26 · 2025-07-02
Summary
The project advances preclinical development of the first non-surgical treatment for Hirschsprung disease, a rare congenital disorder that causes severe gastrointestinal issues and risk of sepsis in affected newborns.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
710310533
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2026-03-27
Agreement Number
1033406
Agreement Start Date
2025-07-02
Agreement Title
Preclinical development of a combination therapy for the treatment of Hirschsprung disease in newborns
Agreement Title (French)
Développement préclinique d’une thérapie combinée pour le traitement de la maladie de Hirschsprung chez les nouveau-nés
Agreement Type
Contribution
Agreement Value
$250,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The project advances preclinical development of the first non-surgical treatment for Hirschsprung disease, a rare congenital disorder that causes severe gastrointestinal issues and risk of sepsis in affected newborns.
Description (French)
Le projet fait progresser le développement préclinique du premier traitement non chirurgical de la maladie de Hirschsprung, une maladie congénitale rare qui provoque de graves troubles gastro-intestinaux et un risque de septicémie chez les nouveau-nés atteints.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding (French)
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number
24077
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
710310533
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
NEURENATI THERAPEUTIQUE INC./NEURENATI THERAPEUTICS INC.
Recipient Postal Code
H3B 1S6
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2025-2026-Q2-1033406
